AI-assisted data: figures and text on this page are extracted from public quarterly
filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop).
They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE /
BSE filings before making any decision. Educational information only, not financial advice.
Sudarshan Pharma Industries Limited reported revenue of ₹217 crore for the quarter ended September 2026 (Q2 FY27), and up 24.4% sequentially over the June 2026 quarter.
Net profit stood at ₹8 crore. Earnings per share (EPS) came in at ₹0.31.
Operating profit stood at ₹21 crore — an operating margin (OPM) of 9.5%.
Valuation snapshot
At the current price of ₹32.20, SUDARSHAN has a market capitalisation of ₹798 crore.
Price history not availableDaily price data has not been backfilled for this symbol yet.
📊 Quarterly trend
₹ crore · OPM % on right axis
Not enough data to chartQuarterly figures have not been extracted for this symbol yet.
🎯 Key metrics
price-linked ratios use the latest close
Valuation
Market Cap ?
₹798 Cr
Current Price ?
₹32.2
P/E ?
N/A
Industry P/E ?
27.40
P/B ?
4.08
P/S ?
N/A
P/FCF ?
N/A
Enterprise Value ?
₹1,190 Cr
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
N/A
Dividend Yield ?
N/A
Profitability & Returns
Sales (TTM) ?
N/A
OPM ?
N/A
Profit after tax (TTM) ?
N/A
EPS (TTM) ?
N/A
ROCE ?
N/A
ROE ?
N/A
ROA ?
N/A
Growth
Sales — latest qtr ?
₹217 Cr
PAT — latest qtr ?
₹8 Cr
YoY qtr sales growth ?
N/A
YoY qtr profit growth ?
N/A
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹392 Cr
Debt to Equity ?
2.01
Interest Coverage ?
N/A
Ownership
Promoter holding ?
N/A
Change in promoter holding ?
N/A
FII holding ?
N/A
DII holding ?
N/A
Market
Return 3 months ?
-15.1%
Return 6 months ?
-15.1%
🗓️ Quarterly results (2 quarters · ₹ Cr)
same fiscal quarter as Sepbestweakestper row · for costs (interest, NPAs) low is best
Metric
Jun 2026
Sep 2026
YoY %
QoQ %
Sales
174
217
—
+24.4%
Operating Profit
16
21
—
+29.4%
Other Income
1
2
—
+58.4%
Interest
8
10
—
+26.2%
Depreciation
1
1
—
-3.6%
Profit Before Tax
8
11
—
+43.9%
Net Profit
6
8
—
+38.7%
EPS
0.23
0.31
—
+34.8%
OPM %
9.1%
9.5%
—
+4.4%
📆 Annual results (₹ Cr, FY = Apr–Mar)
Annual rollup not yet available
We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.
🏛️ Balance Sheet (latest 1 periods)
Metric
Sep 2026
% Chg
Equity Capital
25
—
Reserves
170
—
Borrowings
392
—
Other Liabilities
175
—
Total Liabilities
762
—
Fixed Assets
99
—
CWIP
8
—
Investments
0
—
Other Assets
655
—
Total Assets
762
—
📦 Working Capital (latest 1 periods)
Metric
Sep 2026
% Chg
Inventories
254
—
Trade Receivables
251
—
Trade Payables
160
—
💧 Half-year Cash Flow (latest 1 periods)
Metric
Sep 2026
% Chg
Cash from Operating Activity
-53
—
Cash from Investing Activity
-69
—
Cash from Financing Activity
121
—
Net Cash Flow
0
—
⚖️ Peer comparison
Industry: Specialty Chemicals · top 25 of 68 companies ·
full page →
What was Sudarshan Pharma Industries Limited's revenue in Q2 FY27?
Sudarshan Pharma Industries Limited reported revenue of ₹217 crore for the quarter ended September 2026 (Q2 FY27), and up 24.4% sequentially over the June 2026 quarter.
What was Sudarshan Pharma Industries Limited's net profit in Q2 FY27?
Net profit stood at ₹8 crore. Earnings per share (EPS) came in at ₹0.31.
What is SUDARSHAN's market capitalisation and P/E ratio?
At the current price of ₹32.20, SUDARSHAN has a market capitalisation of ₹798 crore.
TTM ends N/A. Amounts are ₹ crore unless stated otherwise.
Figures are extracted by AI from public quarterly filings; gaps are filled from public market data.
Live price from exchange data. Educational information only — not financial advice.
⚠️How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI
⚡ Free FlashFinance Newsletters
AI-powered market intelligence in your inbox — completely free. Pick your topics; max 1 email per topic per day. Unsubscribe anytime.
✅ Everything below is 100% free — no payment, no card, ever.
🎉
You're subscribed!
A welcome email with your topics is on its way. Want it even faster? Join us on Telegram or WhatsApp: